Status:

COMPLETED

Optic Neuritis Recovery After Oral or IV Corticosteroids

Lead Sponsor:

London Health Sciences Centre

Collaborating Sponsors:

The Physicians' Services Incorporated Foundation

Conditions:

Optic Neuritis

Eligibility:

All Genders

18-64 years

Phase:

PHASE2

PHASE3

Brief Summary

Patients aged 18-65 with acute demyelinating optic neuritis where treatment with high dose corticosteroids are already been chosen by the patient and the diagnosing physician will be contacted for scr...

Detailed Description

This will be a single-blind, randomized comparison study between 1000mg IV methylprednisolone daily for three days and 1250mg oral prednisone daily for three days of the recovery of optic nerve functi...

Eligibility Criteria

Inclusion

  • Males/Females who are ≥ 18 years old and \< 65 years old and are capable of understanding and complying with the protocol
  • Have a diagnosis of unilateral acute demyelinating optic neuritis and will be treated with high dose corticosteroids
  • Are within 14 days of symptom onset
  • Have a visual acuity in the affected of eye of ≥ 20/40
  • Have not received corticosteroids in the last thirty (30) days
  • Medications that could potentially affect the VEP P100 amplitude or may cause drowsiness/difficulty with visual fixation are allowed if there has been no change in dose within 30 days of study enrollment or anytime during the study. These medications include:
  • Carbamazepine or other anticonvulsants (45)
  • Benzodiazepines
  • Opioid and opiates
  • Barbiturates
  • Sleep aids such as zopiclone or trazadone
  • Tricyclic antidepressants
  • Have given written informed consent prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care

Exclusion

  • Have another medical condition that could affect the visual outcomes, such as, but not limited to, diabetes retinopathy, glaucoma, cataracts and optic neuropathy not due to a demyelinating lesion
  • Have had optic neuritis in the same eye previously

Key Trial Info

Start Date :

March 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2015

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT01524250

Start Date

March 1 2012

End Date

May 1 2015

Last Update

September 2 2015

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

London Health Sciences Center

London, Ontario, Canada, N6A 5A5

2

London Health Sciences Center

London, Ontario, Canada, N6G1W8